Overview
- An international consensus of clinicians and advocates advanced the new name after a long consultation that culminated in a Lancet publication and broad professional backing.
- Experts say polyendocrine metabolic ovarian syndrome better signals insulin resistance and cardiovascular risk rather than cysts, which are actually immature follicles and are not required for diagnosis.
- Diagnostic criteria do not change for now, and groups plan a staged three‑year rollout to update education, guidelines, and health‑system terminology.
- Doctors are urging routine screening for diabetes, cholesterol, blood pressure, sleep problems, and mental health, with multidisciplinary care across endocrinology, gynecology, dermatology, nutrition, and psychology.
- The condition affects roughly one in eight women worldwide, many remain undiagnosed for years, and patients describe delays and stigma that supporters hope the reframe will reduce.